Bremelanotide injection is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women who previously had no problems with sexual desire and that occurs in any type of stimulation, situation, or partner. It should only be used in women who have low sexual desire that is troubling to them and is not caused by a medical or mental health problem, problems in the relationship, or medicine or other drug use.

Uses

Bremelanotide is used for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.Specifically it is only recommended in those who have the condition without an underlying cause, such as medical, psychiatric, or relationship problems.

It should be used at least 45 minutes before anticipated sexual activity.Only one dose per 24 hours or no more than eight doses per month is recommended.It should be stopped after eight weeks if there is no improvement in sexual desire and associated distress.

Drug Interactions

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Side Effects

The most frequently encountered side effect of bremelanotide is nausea (40.0%), which may be intolerable to some people.The use of anti-nausea medications (e.g. ondansetron) prior to administration of bremelanotide may help to reduce the nausea.Other side effects may include flushing (20.3%), injection site reactions (13.2%), headache (11.3%), vomiting (4.8%), cough (3.3%), fatigue (3.2%), hot flushes (2.7%), paresthesia (2.6%), dizziness (2.2%), and nasal congestion (2.1%).Discoloration of the skin, specifically hyperpigmentation, may occur—especially if bremelanotide is used more than eight times in one month. The discoloration may not resolve upon stopping use of bremelanotide, and may occur on the face, gums, or breasts.Experiments in animals, even at high doses, failed to find any negative consequence of bremelanotide on fertility.